On September 30, 2022, the President signed into law the FDA User Fee Reauthorization Act of 2022.
Similar Posts
Stokes Healthcare Inc. dba Epicur Pharma. Mount Laurel, NJ. 483 issued 05/23/2025
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 05/23/2025
Short Title (70 char) Stokes Healthcare Inc. dba Epicur Pharma. Mount Laurel, NJ. 483 issued 05/23/2025
FEI Number 3002815949
Firm Name Stokes Healthcare Inc. dba Epicur Pharma
Record Type 483
State NNatural MiracleZEN GOLD 60000 contains hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Natural MiracleZEN GOLD 60000, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.Ongoing Clinical Oncology Projects
Clinical projects of the Oncology Center of Excellence, 2023 Annual ReportAbsolutely Natural – 715690 – 12/30/2025
CGMP/Finished Pharmaceuticals/AdulteratedCANCELED – 17th Annual Sentinel Initiative Public Workshop – 11/06/2025
The U.S. Food and Drug Administration, under a cooperative agreement with the Duke-Margolis Institute for Health Policy, is hosting the 16th Annual Sentinel Initiative Public Workshop on November 6, 2025Generic Drug Research Priorities & Projects
In accordance with the Generic Drug User Fee Amendments (GDUFA), FDA consults with industry and the public to create an annual list of regulatory science initiatives on generic drugs. These priorities are discussed and developed in public meetings and workshops, resulting in several awarded projects